Sotatercept for the treatment of portopulmonary hypertension: a case report - PubMed
3 hours ago
- #Case Report
- #Sotatercept
- #Portopulmonary Hypertension
- Portopulmonary Hypertension (PoPH) is a severe subtype of pulmonary arterial hypertension with high mortality and limited treatment options.
- Sotatercept, a novel activin signaling inhibitor, has shown efficacy in pulmonary arterial hypertension but was not tested in PoPH patients in clinical trials.
- This case report describes the first use of Sotatercept in a PoPH patient, showing improved hemodynamics but possible association with hepatopulmonary syndrome.
- Single-cell RNA sequencing and plasma proteomic analysis revealed changes in CD8+ T-Cell and Monocyte gene expression and inflammatory protein levels post-treatment.
- The report highlights the potential benefits and risks of Sotatercept in PoPH, suggesting further investigation is needed.